{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:27:25Z","timestamp":1790519245540,"version":"4.1.0"},"reference-count":49,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100019832","name":"Galapagos NV","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2019,5,2]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve quality of life. Here we report the design of two phase III studies of the novel IPF therapy, GLPG1690.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>Two identically designed, phase III, international, randomised, double-blind, placebo-controlled, parallel-group, multicentre studies (ISABELA 1 and 2) were initiated in November 2018. It is planned that, in each study, 750 subjects with IPF will be randomised 1:1:1 to receive oral GLPG1690 600 mg, GLPG1690 200 mg or placebo, once daily, on top of local SOC, for at least 52 weeks. The primary endpoint is rate of decline of forced vital capacity (FVC) over 52 weeks. Key secondary endpoints are week 52 composite endpoint of disease progression or all-cause mortality (defined as composite endpoint of first occurrence of \u226510% absolute decline in per cent predicted FVC or all-cause mortality at week 52); time to first respiratory-related hospitalisation until end of study; and week 52 change from baseline in the St George\u2019s Respiratory Questionnaire total score (a quality-of-life measure).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Studies will be conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and local ethical and legal requirements. Results will be reported in a peer-reviewed publication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03711162\">NCT03711162<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03733444\">NCT03733444<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2019-000422","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T18:15:34Z","timestamp":1558462534000},"page":"e000422","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":84,"title":["Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct03711162","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03733444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03711162","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03733444","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"first","affiliation":[{"name":"NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Centre for Interstitial and Rare Lung Diseases, Thoraxklinik, University Hospital Heidelberg, and German Center for Lung Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Lederer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[{"name":"Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Verbruggen","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Stutvoet","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Fieuw","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ford","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Abi-Saab","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"issue":"11 Suppl","key":"2025083111105957000_6.1.e000422.1","first-page":"S176","article-title":"Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines","volume":"23","author":"Sharif","year":"2017","journal-title":"Am J Manag Care"},{"key":"2025083111105957000_6.1.e000422.2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025083111105957000_6.1.e000422.3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","volume":"9","author":"Wolters","year":"2014","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2025083111105957000_6.1.e000422.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2025083111105957000_6.1.e000422.5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120362","article-title":"Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"key":"2025083111105957000_6.1.e000422.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2025083111105957000_6.1.e000422.7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00148","article-title":"The management of patients with idiopathic pulmonary fibrosis","volume":"5","author":"Spagnolo","year":"2018","journal-title":"Front Med"},{"key":"2025083111105957000_6.1.e000422.8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1183\/09059180.00010905","article-title":"Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling","volume":"17","author":"Chambers","year":"2008","journal-title":"Eur Respir Rev"},{"key":"2025083111105957000_6.1.e000422.9","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.10720.1","article-title":"Recent advances in managing idiopathic pulmonary fibrosis","volume":"6","author":"Scelfo","year":"2017","journal-title":"F1000Res"},{"key":"2025083111105957000_6.1.e000422.10","doi-asserted-by":"crossref","first-page":"pii: 170071","DOI":"10.1183\/16000617.0071-2017","article-title":"Pharmacotherapy for idiopathic pulmonary fibrosis: Current landscape and future potential","volume":"26","author":"Raghu","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2025083111105957000_6.1.e000422.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2025083111105957000_6.1.e000422.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2025083111105957000_6.1.e000422.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083111105957000_6.1.e000422.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025083111105957000_6.1.e000422.15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"2025083111105957000_6.1.e000422.16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"issue":"3-b Suppl","key":"2025083111105957000_6.1.e000422.17","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2025083111105957000_6.1.e000422.18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli","year":"2017","journal-title":"Respirology"},{"key":"2025083111105957000_6.1.e000422.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"key":"2025083111105957000_6.1.e000422.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-015-0034-y","article-title":"Comparing new treatments for idiopathic pulmonary fibrosis \u2013 a network meta-analysis","volume":"15","author":"Loveman","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2025083111105957000_6.1.e000422.21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1753465816686743","article-title":"Optimizing quality of life in patients with idiopathic pulmonary fibrosis","volume":"11","author":"van Manen","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"2025083111105957000_6.1.e000422.22","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0235ED"},{"key":"2025083111105957000_6.1.e000422.23","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0155OC"},{"key":"2025083111105957000_6.1.e000422.24","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00180","article-title":"Autotaxin in pathophysiology and pulmonary fibrosis","volume":"5","author":"Ninou","year":"2018","journal-title":"Front Med"},{"key":"2025083111105957000_6.1.e000422.25","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0004OC"},{"key":"2025083111105957000_6.1.e000422.26","doi-asserted-by":"publisher","DOI":"10.1038\/nm1685"},{"key":"2025083111105957000_6.1.e000422.27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00032"},{"key":"2025083111105957000_6.1.e000422.28","article-title":"Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis","volume":"193","author":"van der Aah","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083111105957000_6.1.e000422.29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2A randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025083111105957000_6.1.e000422.30","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083111105957000_6.1.e000422.31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025083111105957000_6.1.e000422.32","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2025083111105957000_6.1.e000422.33","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2025083111105957000_6.1.e000422.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2025083111105957000_6.1.e000422.35","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025083111105957000_6.1.e000422.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201581"},{"key":"2025083111105957000_6.1.e000422.37","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2025083111105957000_6.1.e000422.38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1513\/AnnalsATS.201703-244FR","article-title":"The value and application of the 6-minute-walk test in idiopathic pulmonary fibrosis","volume":"15","author":"Brown","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2025083111105957000_6.1.e000422.39","first-page":"907","article-title":"AARC clinical practice guideline. Exercise testing for evaluation of hypoxemia and\/or desaturation. American Association for respiratory care","volume":"37","year":"1992","journal-title":"Respir Care"},{"key":"2025083111105957000_6.1.e000422.40","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"2025083111105957000_6.1.e000422.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-017-0468-5","article-title":"Unmet needs in the treatment of idiopathic pulmonary fibrosis\u2014insights from patient chart review in five European countries","volume":"17","author":"Maher","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2025083111105957000_6.1.e000422.42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000490667","article-title":"Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views","volume":"96","author":"Maher","year":"2018","journal-title":"Respiration"},{"key":"2025083111105957000_6.1.e000422.43","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2817"},{"key":"2025083111105957000_6.1.e000422.44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/rccm.201709-1939ED","article-title":"Combination therapy and the start of a new epoch for idiopathic pulmonary fibrosis?","volume":"197","author":"Maher","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083111105957000_6.1.e000422.45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025083111105957000_6.1.e000422.46","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"key":"2025083111105957000_6.1.e000422.47","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200211-1311OC"},{"key":"2025083111105957000_6.1.e000422.48","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200209-1112OC"},{"key":"2025083111105957000_6.1.e000422.49","doi-asserted-by":"crossref","DOI":"10.1186\/2049-6958-7-42","article-title":"Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges","volume":"7","author":"Spagnolo","year":"2012","journal-title":"Multidiscip Respir Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2019-000422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:11:12Z","timestamp":1756663872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2019-000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,5,21]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bmjresp-2019-000422"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2019-000422","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}